IDT Biologika has developed and is marketing the first swine influenza vaccine – Respiporc Flu3 – registered for protection against the three most clinically significant subtypes of the virus, H1N1, H3N2 and H1N2.
“For the first time we are able to market a vaccine which also provides protection against the new swine flu virus subtype, H1N2,” commented Dr Gert Barysch, IDT Biologika’s CEO for animal health.
Marketing authorisation IDT Biologika, based in Dessau-Rosslau, Germany, has obtained European-wide marketing authorisation through the centralised registration procedure and initially will be selling Respiporc Flu3 in Germany, Austria and Poland. Other countries will follow subsequently. IDT’s new trivalent vaccine is also being marketed under licence in selected European countries under a different trade name.